期刊文献+
任意字段
题名或关键词
题名
关键词
摘要
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息
共找到600篇文章
< 1 2 … 30 >
每页显示 20 50 100
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
显示方式：
Antithrombin reduces reperfusion-induced hepatic metastasis of colon cancer cells 认领 引用 被引量：8
1
作者 Masanao Kurata Kenji Okajima +2 位作者 Toru Kawamoto Mitsuhiro Uchiba Nobuhiro Ohkohchi 《World Journal of Gastroenterology》 SCIE CAS 2006年第1期60-65,共6页
AIM： To examine whether antithrombin （AT） could prevent hepatic ischemiaeperfusion （I/R）-induced hepatic metastasis by inhibiting tumor necrosis factor （TNF）-α-induced expression of E-selectin in rats. METHODS... AIM： To examine whether antithrombin （AT） could prevent hepatic ischemiaeperfusion （I/R）-induced hepatic metastasis by inhibiting tumor necrosis factor （TNF）-α-induced expression of E-selectin in rats. METHODS： Hepatic I/R was induced in rats and mice by clamping the left branches of the portal vein and the hepatic artery. Cancer cells were injected intrasplenically. The number of metastatic nodules was counted on day 7 after I/R. TNF-α and E-selectin mRNA in hepatic tissue, serum fibrinogen degradation products and hepatic tissue levels of 6-keto-PGF1α, a stable metabolite of PGI2, were measured. RESULTS： AT inhibited increases in hepatic metastasis of tumor cells and hepatic tissue mRNA levels of TNF-α and E-selectin in animals subjected to hepatic I/R. Argatroban, a thrombin inhibitor, did not suppress any of these changes. Both AT and argatroban inhibited I/R-induced coagulation abnormalities. I/R-induced increases of hepatic tissue levels of 6-keto-PGF1α were significantly enhanced by AT. Pretreatment with indomethacin completely reversed the effects of AT. Administration of OP-2507, a stable PGI2 analog, showed effects similar to those of AT in this model. Hepatic metastasis in congenital AT-deficient mice subjected to hepatic I/R was significantly increased compared to that observed in wild-type mice. Administration of AT significantly reduced the number of hepatic metastases in congenital AT-deficient mice. CONCLUSION： AT might reduce I/R-induced hepatic metastasis of colon cancer cells by inhibiting TNF-α-induced expression of E-selectin through an increase in the endothelial production of PGI2. These findings also raise the possibility that AT might prevent hepatic metastasis of tumor cells if administered during the resection of liver tumors. 展开更多
关键词 Antithrombin,reperfusion Metastasis factor-aE-selectin Hepatic ischemia/Prostacyclin Tumor necrosis factor-α
暂未订购 下载PDF
Antithrombin gene Arg197Stop mutation-associated venous sinus thrombosis in a Chinese family 认领 引用 被引量：1
2
作者 Ang Li Tianhui Liu +9 位作者 Zhandong Liu Jimei Li Chunling Zhang Jun Chen Jinmei Sun Yanfei Han Lili Wang Dexin Wang Qiming Xue Baoen Wang 《Neural Regeneration Research》 SCIE CAS CSCD 2011年第20期1575-1579,共5页
This study sought to elucidate the genetic correlation of cerebral venous sinus thrombosis caused by a hereditary antithrombin deficiency in a Chinese family, at the genetic and protein levels. A nonsense mutation fro... This study sought to elucidate the genetic correlation of cerebral venous sinus thrombosis caused by a hereditary antithrombin deficiency in a Chinese family, at the genetic and protein levels. A nonsense mutation from C to T on locus 6431 in exon 3B of the antithrombin gene was observed, leading to an arginine （CGA） to stop codon （TGA） change in the protein. This is the first report of this mutation in China. Ineffective heparin therapy in the propositus patient is associated with a lack of heparin binding sites after antithrombin gene mutation. Characteristic low intracranial pressure in the acute phase might be specific to this patient with cerebral venous sinus thrombosis. 展开更多
关键词 antithrombin cerebral venous sinus thrombosis intracranial hypotension nonsense mutation brain edema
暂未订购 下载PDF
Pharmacokinetic and Pharmacodynamic Properties of Batifiban Coadministered with Antithrombin Agents in Chinese Healthy Volunteers 认领 引用 被引量：1
3
作者 何晓梦 周莹 +8 位作者 李杰 伍三兰 贾萌萌 刘明周 谌辉 谌科 李圣峰 王耀华 黎维勇 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 2013年第5期786-790,共5页
The combined use of batifiban, a synthetic platelet GP II b/IIIa receptor antagonist, and an- tithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation （NSTE） acute corona... The combined use of batifiban, a synthetic platelet GP II b/IIIa receptor antagonist, and an- tithrombin agents is an attractive option for the treatment of patients with non-ST-segment elevation （NSTE） acute coronary syndrome （ACS） and those scheduled for percutaneous coronary intervention. To observe whether antithrombin agents affect the pharmacokinetic and pharmacodynamic properties of batifiban in combination therapy and optimize clinical administration dosage of batifiban, an open-label and parallel study was conducted. Thirty healthy subjects were randomly divided into three groups, which were sequentially treated with batifiban alone, or oral coadministration of clopidogrel, aspirin and UFH, or batifiban coadministered with these antithrombin agents. Blood samples were collected at pre-specified time points. The evaluation index included the inhibition of platelet aggregation and pharmacokinetic parameters. The pharmacokinetic parameters of batifiban and batifiban coadministered with antithrombin agents showed no significant differences. The mean inhibition rate of platelet aggre- gation （%） suggested that neither batifiban alone nor antithrombin agents alone could provide such po- tent inhibition rate （〉80%） to obtain the best clinical efficacy, but they had a synergistic effect on plate- let inhibition. No serious adverse effects were observed. The results in these healthy subjects suggest that batifiban coadministrated with antithrombin agents could achieve optimum clinical treatment effect for patients with NSTE ACS, and also those scheduled for percutaneous coronary intervention. 展开更多
关键词 batifiban glycoprotein II b/Ilia inhibitors antithrombin agents pharmacokinetics phar- macodynamics
暂未订购 下载PDF
High Performance Affinity Chromatography of Antithrombin III Based on Monodisperse Poly (glycidyl methacrylate) Beads 认领 引用
4
作者 Ying Xin ZHAO Di Hua SHANGGUAN +2 位作者 Rui ZHAO Tian Sheng SHU Guo Quan LIU 《Chinese Chemical Letters》 SCIE CAS 2001年第5期443-446,共4页
A new approach for the separation of antithrombin III with high performance affinity chromatography (HPAC) was described. A novel monodisperse, non-porous, cross-linked poly (glycidyl methacrylate) beads (PGMA) were u... A new approach for the separation of antithrombin III with high performance affinity chromatography (HPAC) was described. A novel monodisperse, non-porous, cross-linked poly (glycidyl methacrylate) beads (PGMA) were used as the affinity support. With the water-soluble carbodiimide, heparin was linked covalently to amino-PGMA-beads, which was prepared by amination of PGMA. The adsorbent obtained exhibits high binding activity to antithrombin III (ATIII), good resolution and excellent mechanical properties and can be used under high flow rate. 展开更多
关键词 High performance affinity chromatography antithrombin III heparin
暂未订购 下载PDF
Antithrombin in the treatment of burn trauma 认领 引用 被引量：5
5
作者 Areta Kowal-Vern Bruce A Orkin 《World Journal of Critical Care Medicine》 2016年第1期17-26,共10页
Antithrombin(AT) is a natural anticoagulant with antiinflammatory properties that has demonstrated value in sepsis, disseminated intravascular coagulation and in burn and inhalation injury. With high doses, AT maydecr... Antithrombin(AT) is a natural anticoagulant with antiinflammatory properties that has demonstrated value in sepsis, disseminated intravascular coagulation and in burn and inhalation injury. With high doses, AT maydecrease blood loss during eschar excision, reducing blood transfusion requirements. There are no human randomized, placebo-controlled studies, which have tested the true benefit of this agent in these conditions. Two main forms of AT are either plasma-derived AT(ph AT) and recombinant AT(rh AT). Major ovine studies in burn and smoke inhalation injury have utilized rh AT. There have been no studies which have either translated the basic rh AT research in burn trauma, or determined the tolerance and pharmacokinetics of rh AT concentrate infusions in burn patients. Advantages of rh AT infusions are no risk of blood borne diseases and lower cost. However, the majority of human burn patient studies have been conducted utilizing ph AT. Recent Japanese clinical trials have started using ph AT in abdominal sepsis successfully. This review examines the properties of both ph AT and rh AT, and analyzes studies in which they have been utilized. We believe that it is time to embark on a randomized placebo-controlled multi-center trial to establish the role of AT in both civilian and military patients with burn trauma. 展开更多
关键词 Antithrombin Burn trauma Burn injury Inhalation injury Recombinant antithrombin
暂未订购 下载PDF
Antithrombin Ⅲ deficiency in a patient with recurrent venous thromboembolism:A case report 认领 引用
6
作者 Jia-Qing Luo Shuai-Shuai Mao +5 位作者 Jin-Yi Chen Xue-Ying Ke Yue-Feng Zhu Wei Huang Hai-Ming Sun Zhen-Jie Liu 《World Journal of Clinical Cases》 SCIE 2023年第20期4956-4960,共5页
BACKGROUND Antithrombin Ⅲ(AT3)deficiency,an autosomal dominant disease,increases the likelihood of an individual developing venous thromboembolism(VTE).Longterm anticoagulation treatment is required for those sufferi... BACKGROUND Antithrombin Ⅲ(AT3)deficiency,an autosomal dominant disease,increases the likelihood of an individual developing venous thromboembolism(VTE).Longterm anticoagulation treatment is required for those suffering from AT3 deficiency.CASE SUMMARY A man aged 23,who had a history of deep venous thrombosis(DVT),experienced recurrent pain and swelling in his right lower extremity for three days following withdrawal of Rivaroxaban.He was diagnosed with DVT and antithrombin Ⅲ deficiency as genetic testing revealed a single nucleotide variant in SERPINC1(c.667T>C,p.S223P).The patient was advised to accept long-term anticoagulant therapy.CONCLUSION Inherited AT3 deficiency due to SERPINC1 mutations results in recurrent VTE.Patients may benefit from long-term anticoagulant therapy. 展开更多
关键词 Antithrombin Venous thrombosis SERPINC1 Single nucleotide variant Anticoagulant therapy Case report
暂未订购 下载PDF
Antithrombin Ⅲ injection via the portal vein suppresses liver damage 认领 引用 被引量：2
7
作者 Masayuki Miyazaki Masaki Kato +8 位作者 Masatake Tanaka Kosuke Tanaka Shinichiro Takao Motoyuki Kohjima Tetsuhide Ito Munechika Enjoji Makoto Nakamuta Kazuhiro Kotoh Ryoichi Takayanagi 《World Journal of Gastroenterology》 SCIE CAS CSCD 2012年第16期1884-1891,共8页
AIM:To investigate the effects of antithrombin Ⅲ(AT Ⅲ) injection via the portal vein in acute liver failure.METHODS:Thirty rats were intraperitoneally challenged with lipopolysaccharide(LPS) and D-galactosamine(GalN... AIM:To investigate the effects of antithrombin Ⅲ(AT Ⅲ) injection via the portal vein in acute liver failure.METHODS:Thirty rats were intraperitoneally challenged with lipopolysaccharide(LPS) and D-galactosamine(GalN) and divided into three groups:a control group;a group injected with AT Ⅲ via the tail vein;and a group injected with AT Ⅲ via the portal vein.AT Ⅲ(50 U/kg body weight) was administrated 1 h after challenge with LPS and GalN.Serum levels of inflammatory cytokines and fibrin degradation products,hepatic fibrin deposition,and hepatic mRNA expression of hypoxiarelated genes were analyzed.RESULTS:Serum levels of alanine aminotransferase,tumor necrosis factor-α and interleukin-6 decreased significantly following portal vein AT Ⅲ injection compared with tail vein injection,and control rats.Portal vein AT Ⅲ injection reduced liver cell destruction and decreased hepatic fibrin deposition.This treatment also significantly reduced hepatic mRNA expression of lactate dehydrogenase and heme oxygenase-1.CONCLUSION:A clinically acceptable dose of AT Ⅲ injection into the portal vein suppressed liver damage,probably through its enhanced anticoagulant and antiinflammatory activities. 展开更多
关键词 Antithrombin Ⅲ Acute liver failure Intravascular coagulation Portal vein
暂未订购 下载PDF
Impact of antithrombin Ⅲ on hepatic and intestinal microcirculation in experimental liver cirrhosis and bowel inflammation: An in vivo analysis 认领 引用 被引量：1
8
作者 Sasa-Marcel Maksan Zilfi lger +1 位作者 Martha Maria Gebhard Jan Schmidt 《World Journal of Gastroenterology》 SCIE CAS 2005年第32期4997-5001,共5页
AIM： To analyze the hepatic and intestinal microcirculation in an animal model of liver cirrhosis and inflammatory bowel disease （IBD） and to characterize bhe anti-inflammatory action of antithrombin Ⅲ （ATⅢ） on... AIM： To analyze the hepatic and intestinal microcirculation in an animal model of liver cirrhosis and inflammatory bowel disease （IBD） and to characterize bhe anti-inflammatory action of antithrombin Ⅲ （ATⅢ） on leukocyte kinetics and liver damage. METHODS： Hepatic and intestinal microcirculation was investigated by intravital videomicroscopy. Standardized models of experimental chronic liver cirrhosis and bowel inflammation were employed. Animals were divided into four groups （n = 6/group）： controls, animals with cirrhosis, animals with cirrhosis and IBD, animals with cirrhosis and IBD treated with ATIII. RESULTS： Cirrhosis facilitated leukocyte rolling and sticking in hepatic sinusoids （1.91±0.28 sticker/μm vs 0.5±0.5 sticker/μm in controls, P〈0.05）. The effect enhanced in animals with cirrhosis and IBD （5.4±1.65 sticker/μm）, but reversed after ATIII application （3.97±1.04 sticker/μm, P〈0.05）. Mucosal blood flow showed no differences in cirrhotic animals and controls （5.3±0.31 nL/min vs5.4±0.25 nL/min） and was attenuated in animals wibh cirrhosis and IBD significantly （3.49±0.6 nL/min）. This effect was normalized in the treatment group （5.13±0.4 nL/min, P〈0.05）. Enzyme values rose during development of cirrhosis and bowel inflammation, and reduced after ATIII application （P〈0.05）. CONCLUSION： Liver cirrhosis in the presence of IBD leads to a significant reduction in mucosal blood flow and an increase in hepatic leukocyte adherence with consecutive liver injury, which can be prevented by administration of ATⅢ. 展开更多
关键词 Liver cirrhosis Microcirculation Bowel inflammation Liver Antithrombin Ⅲ
暂未订购 下载PDF
Change of Coagulation Factor Ⅷ and Antithrombin Ⅲ Activity in Bank-Stored Blood 认领 引用
9
作者 胡丽华 余忠清 张清 《Journal of Huazhong University of Science and Technology(Medical Sciences)》 2000年第3期263-264,共2页
Coagulation factor Ⅷ and antithrombin Ⅲ activity were detected in 15 health donors. It was found that antithrombin Ⅲ activity decreased obviously 12 h after blood drawing. It lost 56 % of the activity at the 3rd da... Coagulation factor Ⅷ and antithrombin Ⅲ activity were detected in 15 health donors. It was found that antithrombin Ⅲ activity decreased obviously 12 h after blood drawing. It lost 56 % of the activity at the 3rd day, and 70 % of the activity at the 7th day. FⅧ:c showed no obvious change after 24 h, until the 3rd day. It lost 40 %-60 % of the activity after 36 h and was reduced to the 30 % of the original activity at the 5th day. Our results suggested that at the 3rd day coagulation factor Ⅷ of bank stored blood can be used to replenish antithrombin Ⅲ, while bank stored blood in one day can be used to replenish FⅧ. 展开更多
关键词 blood storage antithrombin Ⅲ coagulation factor Ⅷ
暂未订购 下载PDF
The Mesenteric-Caval Fistula: First Results of a New Technique in a Transperitoneal Reconstruction of the Caval Vein by Fulminant Thrombosis of the Inferior Vena Cava Based on Homozygous Antithrombin III-Deficiency 认领 引用
10
作者 Justus Gross Rainer Petzina +6 位作者 Rouven Berndt Bernd Panholzer Andreas Bayer Katharina Huenges Leonie Aschauer Jochen Cremer Rene Rusch 《Surgical Science》 2016年第8期342-347,共6页
Recurrent thrombotic occlusions are one major problem in patients with thrombosis of the inferior vena cava. Due to this, we report a new surgical strategy for the construction of aorto-caval (mesenteric-caval) fistul... Recurrent thrombotic occlusions are one major problem in patients with thrombosis of the inferior vena cava. Due to this, we report a new surgical strategy for the construction of aorto-caval (mesenteric-caval) fistula in a patient with homozygous Antithrombin III (ATIII)-Deficiency. The patient survived postoperatively and only surgical complications grade I and II (Clavien-Dindo classification) were reported after short-term and one year follow-up. After one year, the CT-angiography did not show any caval thrombosis or stenosis and no restriction or occlusion of the fistula. Thus, the mesenteric-caval fistula could be safely performed and resulted in a satisfactory patency. 展开更多
关键词 Mesenteric-Caval Fistula Thrombosis Transperitoneal Reconstruction Homozygous Antithrombin III-Deficiency
暂未订购 下载PDF
Identifying dynamic antithrombinⅢtrajectories to predict clinical outcomes in intra-abdominal sepsis 认领 引用
11
作者 Yuteng Ma Yini Sun +6 位作者 Chaoyang Wang Siang Huang Qian Gao Qianyi Xu Mu Sun Qiaojie Sun Ming Dong 《Journal of Intensive Medicine》 CSCD 2026年第3期284-293,共10页
Background:Intra-abdominal infection(IAI)is the leading cause of sepsis and is often complicated by disseminated intravascular coagulation(DIC),leading to increased mortality.AntithrombinⅢ(ATⅢ),a crucial endogenous ... Background:Intra-abdominal infection(IAI)is the leading cause of sepsis and is often complicated by disseminated intravascular coagulation(DIC),leading to increased mortality.AntithrombinⅢ(ATⅢ),a crucial endogenous anticoagulant,becomes significantly depleted during sepsis due to increased consumption and reduced synthesis.Its levels are closely associated with disease severity and clinical outcomes.Currently,there is a lack of evidence on the dynamic changes of ATⅢand their relationship with the severity and prognosis of sepsis caused by IAI.Methods:This was a prospective observational study.The patients with IAI-induced sepsis admitted to the in-tensive care unit(ICU)of the First Affiliated Hospital of China Medical University between April 20,2017,and December 31,2024,constituted the development cohort.Latent class trajectory modeling(LCTM)was applied to classify patients into different subclasses based on the ATⅢlevel trajectories over the first 7 days after sepsis diagnosis.Clinical characteristics and outcomes were compared among these subclasses.Additionally,the ATⅢtrajectory patterns were validated in an external cohort of IAI patients derived from the China Multicenter Sepsis dataset.Results:Four dynamic ATⅢtrajectory subclasses were identified and further validated by data from the devel-opment cohort(n=779)and the external validation cohort(n=820):Class 1 exhibited initially low ATⅢlevels with a rapid decline during the first 3 days;Class 2 showed initially low ATⅢfollowed by gradual recovery;Class 3 started with normal ATⅢlevels but experienced a sharp decline in the first 3 days;Class 4 maintained ATⅢlevels within the normal range throughout.In the development cohort,patients in Class 1 demonstrated the most pronounced coagulation deterioration,characterized by the lowest platelet counts,significantly prolonged prothrombin time(PT)and activated partial thromboplastin time(APTT),more severe inflammatory response,and elevated lactate levels,with the highest ICU and 30-day mortality.Moreover,Class 1 consistently showed significantly higher SOFA scores within 7 days after sepsis diagnosis compared to other subgroups.Incorporating the identification of Class 1 dynamic trajectory significantly improved the predictive performance for 30-day mortality(area under the curve=0.824,P=0.0015).Conclusions:This prospective cohort study uncovers heterogeneity in ATⅢtrajectories among IAI-induced sepsis,which were closely associated with the disease severity over time.Incorporating Class 1(initial low AT followed by rapid decline)improves the predictive value for sepsis prognosis. 展开更多
关键词 Intra-abdominal infection Sepsis Antithrombin III Trajectory analysis Mortality
Clinical and genetic analysis of two families with combined defect in antithrombin and protein Cgenes 认领 引用
12
作者 GUO Yueli 《China Medical Abstracts(Internal Medicine)》 2026年第2期117-118,共2页
Objective To analyze the clinical characteristics and genetic mutations in two families with combined antithrombin(AT)and protein C(PC)deficiency,and to explore the relationship between the combined SERPINC1 and PROC ... Objective To analyze the clinical characteristics and genetic mutations in two families with combined antithrombin(AT)and protein C(PC)deficiency,and to explore the relationship between the combined SERPINC1 and PROC gene mutations and the disease development.Methods The AT activity(AT:A),AT antigen(AT:Ag),PC activity(PC:A),PC antigen(PC:Ag),and protein S activity(PS:A)of the probands and their family members were measured.Next-generation sequencing(NGS)and CNVplex technology were used to detect point mutations,small deletions or insertions,and CNVs in the coding and regulatory regions of the selected genes,with mutation sites verified by Sanger sequencing. 展开更多
关键词 detect point mutatio next generation sequencing Sanger sequencing cnvplex technology combined antithrombin protein C deficiency combined serpinc proc gene mutations genetic mutations clinical characteristics
暂未订购 下载PDF
High expression and analysis of recombinant human antithrombinⅢ(AT-Ⅲ) from CHO cells 认领 引用
13
《中国输血杂志》 CAS 2001年第S1期
关键词 from CHO cells CHO High expression and analysis of recombinant human antithrombin AT
暂未订购 下载PDF
Combined anticoagulant deficiency causing extrahepatic portal venous obstruction:A case report 认领 引用
14
作者 Arkadeep Dhali Rick Maity +3 位作者 Arijit Sinha Prithviraj Singh Jyotirmoy Biswas Gopal Krishna Dhali 《World Journal of Clinical Cases》 2026年第7期56-64,共9页
BACKGROUND Extrahepatic portal venous obstruction is a major cause of non-cirrhotic portal hypertension in children and young adults.It most commonly results from portal vein thrombosis.While prothrombotic states are ... BACKGROUND Extrahepatic portal venous obstruction is a major cause of non-cirrhotic portal hypertension in children and young adults.It most commonly results from portal vein thrombosis.While prothrombotic states are recognized contributors,combined deficiencies of natural anticoagulants,such as protein C,protein S,and antithrombin III,are exceedingly rare and pose diagnostic and therapeutic challenges.CASE SUMMARY A 27-year-old male presented with an episode of melena and had a background of portal cavernoma cholangiopathy and recurrent variceal bleeding since infancy.Previously,he underwent endoscopic sclerotherapy and proximal lienorenal shunt surgery and later developed shunt thrombosis and ischemic biliary strictures requiring Roux-en-Y hepaticojejunostomy.Upper gastrointestinal endoscopy(UGIE)revealed large esophageal and gastric varices that were managed by endoscopic variceal ligation and sclerotherapy.Following the UGIE,he suffered a seizure with deterioration of sensorium,followed by melena and spikes in temperature.Repeat UGIE revealed no active bleeding source and confirmed obliteration of the previously detected varices.Evaluation identified deficiencies in protein S,protein C,and antithrombin III,for which anticoagulation with enoxaparin was initiated.Despite recent sclerotherapy,anticoagulation precipitated melena.Sigmoidoscopy and capsule endoscopy revealed portal hypertensive colopathy with rectal varices.This was managed surgically by creating mesocaval shunts after which enoxaparin was restarted.No further recurrence of bleeding occurred;the patient was discharged in a stable condition.CONCLUSION This case highlighted the importance of thorough coagulation profiling in extrahepatic portal venous obstruction,particularly in young patients with recurrent thrombotic events.Clinicians must navigate the precarious balance between thrombosis prevention and hemorrhage risk. 展开更多
关键词 Extrahepatic portal venous obstruction Portal vein Portal vein thrombosis Protein S deficiency Protein C deficiency Antithrombin III deficiency Case Report
暂未订购 下载PDF
血清TM、TAT、t-PAIC、PIC变化率对急诊脓毒性休克患者疗效的预测价值 认领 引用 被引量：1
15
作者 高淑君 程钊 张亚君 《海南医学》 CAS 2026年第6期866-871,共6页
目的探讨血清血栓调节蛋白(TM)、凝血酶抗凝酶复合物(TAT)、组织型纤溶酶原激活抑制复合物(t-PAIC)、纤溶酶-抗纤溶酶复合物(PIC)变化率对急诊脓毒性休克患者疗效的预测价值。方法回顾性收集2023年1月至2025年1月濮阳油田总医院收治的25... 目的探讨血清血栓调节蛋白(TM)、凝血酶抗凝酶复合物(TAT)、组织型纤溶酶原激活抑制复合物(t-PAIC)、纤溶酶-抗纤溶酶复合物(PIC)变化率对急诊脓毒性休克患者疗效的预测价值。方法回顾性收集2023年1月至2025年1月濮阳油田总医院收治的256例急诊脓毒性休克患者的临床资料,根据患者治疗28 d的生存预后情况分为预后不良组(n=76)和预后良好组(n=180)。采用SPSS28.0软件对患者进行倾向性评分匹配法(PSM),获取组间协变量均衡的样本。比较匹配后两组患者的血清TM、TAT、t-PAIC、PIC水平及变化率(△TM、△TAT、△t-PAIC、△PIC),采用Logistic回归方程分析影响急诊脓毒性休克患者疗效的因素,采用受试者工作特征(ROC)曲线分析△TM、△TAT、△t-PAIC、△PIC对患者疗效的预测价值,并绘制卡普兰-迈耶(K-M)生存曲线。结果匹配后,入院第1天、第7天,预后不良组患者的血清TM、TAT、t-PAIC、PIC水平分别为(21.58±4.41)TU/mL、(16.11±3.52)TU/mL,(17.59±2.38)ng/mL、(14.04±2.81)ng/mL,(25.34±4.12)ng/mL、(20.77±3.55)ng/mL,(18.64±3.14)μg/mL、(15.23±2.71)μg/mL,明显高于预后良好组的(20.14±4.77)TU/mL、14.05±1.56)TU/mL,(16.61±3.74)ng/mL、(12.23±1.34)ng/mL,(24.46±3.28)ng/mL、(18.52±2.06)ng/mL,(17.89±1.88)μg/mL、(13.61±1.34)μg/mL,△TM、△TAT、△t-PAIC、△PIC分别为(25.34±3.36)%、(20.18±3.36)%、(18.03±3.45)%、(18.29±3.48)%,明显低于预后良好组患者(30.24±4.58)%、(26.37±4.95)%、(24.28±5.33)%、(23.49±4.02)%,差异均有统计学意义(P<0.05);Logistic回归方程分析结果显示,△TM、△TAT、△t-PAIC、△PIC均是急诊脓毒性休克患者疗效的影响因素(P<0.05);ROC曲线分析结果显示,△TM、△TAT、△t-PAIC、△PIC联合预测急诊脓毒性休克患者疗效的AUC为0.897,高于单一预测AUC(P<0.05);根据△TM、△TAT、△t-PAIC、△PIC的截断值分为高值和低值,△TM、△TAT、△t-PAIC、△PIC低值患者的生存率分别是61.54%、58.59%、62.40%、64.57%,明显低于高值患者的79.37%、82.03%、77.86%、75.97%,差异均有统计学意义(P<0.05)。结论△TM、△TAT、△t-PAIC、△PIC是急诊脓毒性休克患者疗效的影响因素,联合检测预测效能高,有助于指导临床诊治,提高患者生存率。 展开更多
关键词 脓毒性休克 血栓调节蛋白 凝血酶抗凝酶复合物 组织型纤溶酶原激活抑制复合物 纤溶酶-抗纤溶酶复合物 变化率
暂未订购 下载PDF
Antithrombin deficiency and decreased protein C activity in a young man with venous thromboembolism: a case report 认领 引用 被引量：1
16
作者 Dong Wang Min Tian +1 位作者 Guanglin Cui Dao Wen Wang 《Frontiers of Medicine》 SCIE CSCD 2018年第3期319-323,共5页
Antithrombin and protein C are two crucial members in the anticoagulant system and play important roles in hemostasis. Mutations in SERPINC1 and PROC lead to deficiency or dysfunction of the two proteins, which could ... Antithrombin and protein C are two crucial members in the anticoagulant system and play important roles in hemostasis. Mutations in SERPINC1 and PROC lead to deficiency or dysfunction of the two proteins, which could result in venous thromboembolism （VTE）. Here, we report a Chinese 22-year-old young man who developed recurrent and serious VTE in cerebral veins, visceral veins, and deep veins of the lower extremity. Laboratory tests and direct sequencing of PROC and SERPINC1 were conducted for the patient and his family members. Coagulation tests revealed that the patient presented type I antithrombin deficiency combined with decreased protein C activity resulting from a small insertion mutation c.848_849insGATGT in SERPINC1 and a short deletion variant c.572 574delAGA in PROC. This combination of the two mutations was absent in 400 healthy subjects each from southern and northern China. Then, we summarized all the mutations of the SERPINC1 and PROC gene reported in the Chinese Han population. This study demonstrates that the combination of antithrombin deficiency and decreased protein C activity can result in severe VTE and that the coexistence of different genetic factors may increase the risk of VTE. 展开更多
关键词 antithrombin deficiency protein C activity mutation variant venous thromboembolism anticoagulants
暂未订购 下载PDF
Biochemical activity and gene analysis of inherited protein C and antithrombin deficiency in two Chinese pedigrees 认领 引用 被引量：3
17
作者 周荣富 傅启华 +5 位作者 王文斌 谢爽 胡翊群 王学锋 王振义 王鸿利 《Chinese Medical Journal》 SCIE CAS 2004年第6期813-817,共5页
Background We identified the gene mutations in two Chinese pedigree of type Ⅰ hereditary protein C deficiency and type Ⅰ hereditary antithrombin deficiency.Methods The plasma level of protein C activity (PC∶A),prot... Background We identified the gene mutations in two Chinese pedigree of type Ⅰ hereditary protein C deficiency and type Ⅰ hereditary antithrombin deficiency.Methods The plasma level of protein C activity (PC∶A),protein C antigen (PC∶Ag),protein S activity,antithrombin activity (AT∶A) and antithrombin antigen (AT∶Ag) of propositi and two family members were detected using ELISA and chromogenic assay,respectively. All exons and intron-exon boundaries of protein C gene and antithrombin gene were analyzed by direct sequencing of the corresponding amplified PCR products in DNA from the propositus. Results The plasma PC∶A and PC∶Ag of propositus 1 was 26% and 1.43 mg/dl,respectively. The PC∶Ag and PC∶A of his father were normal. The decreased PC∶A level was seen in his mother and 4 of his maternal pedigree. PS∶A and AT∶A were all normal in pedigree 1 members. A C5498T heterozygous mutation in exon 3 of protein C gene,resulting in the substitution of Arg for Trp at the 15th amino acid,was identified in propositus 1 and 8 of his relatives. The plasma AT∶A and AT∶Ag of propositus 2 was 48.6% and 10.4 mg/dl,respectively. The reduced AT∶A and AT∶Ag levels were found in his father and 5 of paternal pedigree. PC∶A,PC∶Ag and PS∶A were all in normal range. A heterozygous 13387-9G deletion in exon 6 of antithrombin gene was identified in propositus 2. This mutation introduced a frameshift and a premature stop at codon 426 and existed in 6 members of pedigree 2.Conclusion The C5498T heterozygous mutation in exon 3 of protein C gene,first reported in China,leads to type I hereditary protein C deficiency. The 13387-9G deletion,a novel mutation,can cause antithrombin deficiency and thrombosis. 展开更多
关键词 protein C·antithrombin·gene mutation·thrombosis
血浆AT可用于评估多发性骨髓瘤患者肾损伤及其预后 认领 引用
18
作者 孙常铭 王丽萍 +2 位作者 赵维川 朴宗方 郭轶群 《检验医学》 CAS 2026年第6期597-602,共6页
目的分析血浆抗凝血酶(AT)活性在多发性骨髓瘤(MM)患者肾损伤中的临床意义。方法收集2018年1月—2020年10月承德医学院附属医院60例初诊MM患者(MM组)和60例初诊肾病患者(对照组)。比较不同免疫类型MM患者AT活性差异。根据肌酐水平,将MM... 目的分析血浆抗凝血酶(AT)活性在多发性骨髓瘤(MM)患者肾损伤中的临床意义。方法收集2018年1月—2020年10月承德医学院附属医院60例初诊MM患者(MM组)和60例初诊肾病患者(对照组)。比较不同免疫类型MM患者AT活性差异。根据肌酐水平,将MM组和对照组分别细分为肾功能正常组、肾功能受损组和肾功能正常对照组、肾功能受损对照组。采用Person相关分析评估MM患者AT活性和胱抑素C(Cys C)的相关性。采用受试者工作特征(ROC)曲线评估AT和Cys C诊断MM患者肾损伤的效能。对MM患者进行随访,比较不同AT活性和Cys C水平患者化疗后生存时间差异。结果不同免疫类型MM患者AT活性差异有统计学意义(F=13.144,P<0.05);轻链型、IgG型、lgA型、不分泌型MM患者AT活性依次升高。肾功能正常MM患者血浆AT活性高于肾功能异常MM患者,肾功能正常对照组血浆AT活性高于肾功能受损对照组(P<0.05),肾功能受损组血浆AT活性高于肾功能受损对照组(P<0.05)。肾损伤MM患者AT活性和Cys C呈负相关(r=-0.554,P=0.004)。AT和Cys C诊断MM患者肾损伤的曲线下面积(AUC)分别为0.887和0.625。AT活性正常MM患者治疗后生存时间长于AT活性下降MM患者(P<0.05);AT活性正常Cys C正常MM患者化疗后生存时间长于AT活性下降Cys C升高和AT活性正常Cys C升高MM患者(P<0.05)。结论MM患者血浆AT活性与患者的免疫类型有关;AT活性可用于评估MM患者肾损伤。 展开更多
关键词 抗凝血酶 多发性骨髓瘤 肾损伤 肌酐 胱抑素C
暂未订购 下载PDF
血浆蛋白S、蛋白C和抗凝血酶Ⅲ在复发性流产中的预测价值 认领 引用
19
作者 曾甲子 周桐羽 +4 位作者 曹正 朱宏远 曹妍 卢一凡 翟燕红 《标记免疫分析与临床》 CAS 2026年第4期712-715,共4页
目的 旨在探讨复发性流产患者血浆PS、PC、AT-Ⅲ的水平变化,并分析其对RSA的预测价值。方法 选取2022年1月至2023年12月期间于本院就诊且诊断明确的293例RSA患者纳入RSA组,选取同期303例健康正常妊娠女性作为对照组。比较两组间血浆PS... 目的 旨在探讨复发性流产患者血浆PS、PC、AT-Ⅲ的水平变化,并分析其对RSA的预测价值。方法 选取2022年1月至2023年12月期间于本院就诊且诊断明确的293例RSA患者纳入RSA组,选取同期303例健康正常妊娠女性作为对照组。比较两组间血浆PS、PC、AT-Ⅲ的水平变化;通过ROC曲线分析血浆PS、PC、AT-Ⅲ对RSA的预测效能;采用多因素Logistic回归分析发生RSA的影响因素。结果 复发性流产组血浆PS、PC、AT-Ⅲ水平均低于对照组,且差异均有统计学意义(P<0.05)。多因素Logistic回归分析提示PS、PC是RSA的独立危险因素。血浆PS、PC和AT-Ⅲ联合预测RSA的AUC为0.874(95%CI:0.85~0.90),大于血浆PS、PC和AT-Ⅲ单项预测的0.801(95%CI:0.77~0.84)、0.799(95%CI:0.76~0.83)、0.633(95%CI:0.59~0.68)。结论 血浆PS、PC水平降低是RSA的独立危险因素,血浆PS、PC和AT-Ⅲ联合预测对RSA诊断具有良好的预测价值。 展开更多
关键词 复发性流产 蛋白S 蛋白C 抗凝血酶Ⅲ
暂未订购 下载PDF
人抗凝血酶Ⅲ在遗传性抗凝血酶Ⅲ缺乏症患者中应用的药代动力学研究 认领 引用
20
作者 邹羽真 李魁星 +2 位作者 朱铁楠 左玮 钟文 《血栓与止血学》 CAS 2026年第2期65-70,共6页
目的本研究旨在通过单次给药的药代动力学试验,评价抗凝血酶Ⅲ(antithrombinⅢ,AT-Ⅲ)用于遗传性抗凝血酶缺乏症患者的体内药代药动学特征。方法以50 IU/kg剂量为4例遗传性AT-Ⅲ缺乏症患者单次静脉输注人源AT-Ⅲ,采用非房室模型模拟AT-... 目的本研究旨在通过单次给药的药代动力学试验,评价抗凝血酶Ⅲ(antithrombinⅢ,AT-Ⅲ)用于遗传性抗凝血酶缺乏症患者的体内药代药动学特征。方法以50 IU/kg剂量为4例遗传性AT-Ⅲ缺乏症患者单次静脉输注人源AT-Ⅲ,采用非房室模型模拟AT-Ⅲ在体内的分布和消除过程,并评估外源性抗凝血酶Ⅲ的体内回收率(in vivo recovery,IVR)和半衰期等药代动力学参数。结果IVR为2.09(2.42,1.63)IU·dL-1/IU·kg-1,AT-Ⅲ的体内药代动力学过程符合一级药代药动学特征。消除半衰期为50.66(37.95,62.36)h,总体表观分布容积为52.76(43.23,54.68)dL,总体清除率1.13(0.93,1.67)ml/min。结论国产人源AT-Ⅲ制剂在中国遗传性AT-Ⅲ缺乏症患者中具有符合预期的药代动力学特征,单次缓慢静脉给药后约10~11天可基本消除至基线AT-Ⅲ活性水平。该药物药代动力学特征存在较大个体差异,提示可根据药代动力学参数实施个体化给药。 展开更多
关键词 人抗凝血酶Ⅲ 遗传性抗凝血酶Ⅲ缺乏症 药代动力学
暂未订购 下载PDF
已选0条
引用分析
参考文献
引证文献
 统计分析
检索结果
已选文献
上一页 1 2 … 30 下一页 到第 页
在线咨询 使用帮助 返回顶部 意见反馈